Weekly Digest – January 2025 Weekly Digest – January 2025 29 Dec 2024: IDEAYA Biosciences enters exclusive license with Hengrui Pharma for SHR-4849, a novel Phase 1 DLL3 Topo-I-payload ADC targeting SCLC and NET solid tumors IDEAYA Biosciences has entered […]
Weekly Digest – January 2025 Weekly Digest – January 2025 30 Dec 2024: Duality Biologics announces B7H4 ADC milestone achievement and license exercise by BeiGene BeiGene has exercised its exclusive option to the B7-H4 ADC DB1312/BG-C9074 from Duality Biologics, gaining […]
Weekly Digest – January 2025 Weekly Digest – January 2025 29 Dec 2024: Vincerx Pharma enters into a binding term sheet for a strategic merger with Oqory Vincerx Pharma has entered into a binding term sheet for a proposed merger […]
Weekly Digest – December 2024 Weekly Digest – December 2024 27 Dec 2024: DATROWAY® approved in Japan as the first TROP-2 directed therapy for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer Daiichi Sankyo’s DATROWAY® […]
Weekly Digest – December 2024 Weekly Digest – December 2024 27 Dec 2024: DATROWAY® approved in Japan as the first TROP-2 directed therapy for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer Daiichi Sankyo’s DATROWAY® […]
Weekly Digest – December 2024 Weekly Digest – December 2024 23 Dec 2024: Porton Pharma Solutions and Dragon Sail Pharmaceutical form strategic partnership to build a new ecosystem for ADC drug development, production, and supply chain Porton Pharma Solutions and […]
Weekly Digest – December 2024 Weekly Digest – December 2024 23 Dec 2024: OBI Pharma enters collaboration with GlyTech to expand GlycOBI® enabling technologies outreach in Japan and to advance glycan production OBI Pharma, a global oncology company, and GlyTech, […]
Weekly Digest – December 2024 Weekly Digest – December 2024 20 Dec 2024: WuXi Biologics and Hangzhou DAC signed research service agreement with Aadi Bioscience on three novel ADCs WuXi Biologics and Hangzhou DAC Biotechnology have signed a research service […]
Weekly Digest – December 2024 Weekly Digest – December 2024 26 Dec 2024: IND application for a phase I/II clinical study of anti-HER2 bispecific ADC subcutaneous co-formulation JSKN033 was approved Alphamab Oncology has received approval from the CDE of the […]
Weekly Digest – December 2024 Weekly Digest – December 2024 24 Dec 2024: Datopotamab deruxtecan application in the EU for patients with advanced nonsquamous non-small cell lung cancer voluntarily withdrawn AstraZeneca and Daiichi Sankyo have voluntarily withdrawn their marketing authorization […]
